Ads
related to: what does protease do hiv treatment- HIV Treatment FAQs
Find Answers To Frequently Asked
Questions About HIV And Medication.
- Download Patient Brochure
Find Resources With Important Info
About Treatment And Switching.
- Patient Assistance Info
Discover If You Are Eligible To
Save On An HIV-1 Treatment Option.
- HIV Real Patient Stories
Watch The Stories Of People Who
Share Their Treatment Experiences.
- Sign Up For More Info
Learn About An HIV Treatment Option
Sign Up To Receive Information.
- Learn How Treatment Works
Visit The Patient Website To Learn
How An HIV-1 Treatment Works.
- HIV Treatment FAQs
Search results
Results From The WOW.Com Content Network
The HIV protease is a C2-symmetric homodimeric enzyme consisting of two 99 amino acid monomers. Each monomer contributes an aspartic acid residue that is essential for catalysis, [6] Asp-25 and Asp-25´. The HIV protease has the sequence Asp-Thr-Gly, which is conserved among other
These protease inhibitors prevent viral replication by selectively binding to viral proteases (e.g. HIV-1 protease) and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Protease inhibitors that have been developed and are currently used in clinical practice include:
HIV-1 protease labelled according to its resemblance to an English Bulldog or a fat cat. [7] The blue and cyan-green ribbons depict the peptide backbone of a wild-type ( ) and a mutant ( ) structure, respectively. Mature HIV protease exists as a 22 kDa homodimer, with each subunit made up of 99 amino acids. [1]
The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase ...
Nelfinavir is an orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (K i = 2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection. [2] It was patented in 1992 and approved for medical use in 1997. [3]
Protease-sparing regimen, often abbreviated as PSR, is a method or therapy for treating people infected with HIV that involves a three-drug combination that reduces viral load below the limit of detection while saving protease inhibitors for later use. It is considered a weaker (in terms of quantity and concentration) form of HIV treatment.
Ads
related to: what does protease do hiv treatment